Moderna's new flu vaccine, based on the same mRNA technology used in its COVID-19 shot, showed promising results in a major ...

Seasonal flu-related hospitalizations and outpatient visits reached a 15-year high during the 2024-25 season, according to ...

MRNA's mRNA-1010 flu vaccine outperforms GSK's shot by 26.6% in a large phase III trial of adults 50 and older.

RNA-1010 demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed ...

Spanning nine influenza seasons, these studies enrolled 1862 patients, of whom 954 received the high-dose vaccine and 908 the standard-dose vaccine. Primary outcomes were immunogenicity (measured ...

The Subject Expert Committee (SEC) under the COVID-19 division of the Central Drugs Standard Control Organization (CDSCO) has ...

Vaccination is the most effective way to prevent infection and the more severe outcomes associated with influenza viruses. ... have shown strong immunogenicity against H1N1 experimentally, ...

The H5N1 avian influenza virus has infected birds and mammals around the world. As of June 2025, 70 people have been infected ...

The H5N1 avian influenza virus has infected birds and mammals around the world. As of June 2025, 70 people have been infected ...

In this context, we recently identified a potential new type of physiological mechanism leading to enhanced activation of antiviral immunity in response to virus infection: an influenza A virus ...

Influenza A virus infection increases host transposable element (TE) expression. This study provides evidence that some infection-induced TEs form double-stranded RNAs that accumulate in the cytosol ...

Mortality and economic contraction during the 1918-1920 Great Influenza Pandemic provide plausible upper bounds for outcomes under the coronavirus (COVID-19). Data for 48 countries imply flu-related ...